Search
Denali Therapeutics Inc
DNLIAdd to Watchlist
25.720USD
-0.170-0.66%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
4.08BMarket Cap
LossP/E TTM
More Details of Denali Therapeutics Inc Company
Denali Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal storage diseases. It has developed a technology, called the TransportVehicle (TV), to address the BBB challenge. Its advanced TV-enabled program is tividenofusp alfa (DNL310, ETV:IDS) for the potential treatment of mucopolysaccharidosis II (MPS II or Hunter syndrome). Its TV-enabled clinical development portfolio also includes DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo syndrome) and DNL593 (PTV:PGRN) for frontotemporal dementia-granulin (FTD-GRN). Its small-molecule clinical development portfolio includes BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease; and DNL343 (small molecule eIF2B activator) for amyotrophic lateral sclerosis (ALS). It is also exploring programs in oncology, inflammation, and other diseases.
Denali Therapeutics Inc Info
Ticker SymbolDNLI
Company nameDenali Therapeutics Inc
IPO dateDec 08, 2017
CEOWatts (Ryan J)
Number of employees422
Security typeOrdinary Share
Fiscal year-endDec 08
Address161 Oyster Point Blvd.
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16508668547
Websitehttps://www.denalitherapeutics.com
Ticker SymbolDNLI
IPO dateDec 08, 2017
CEOWatts (Ryan J)
Company Executives of Denali Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.45M
-2.04%
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
806.58K
+0.12%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
358.94K
+1.79%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
79.13K
+8.10%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
33.94K
+18.88%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
32.48K
+19.73%
Dr. Marc Tessier-Lavignec, Ph.D.
Dr. Marc Tessier-Lavignec, Ph.D.
Independent Director
Independent Director
--
--
Mr. Steven E. (Steve) Krognes
Mr. Steven E. (Steve) Krognes
Director
Director
--
--
Ms. Nancy A. Thornberry
Ms. Nancy A. Thornberry
Independent Director
Independent Director
--
--
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Ryan J. Watts, Ph.D.
Dr. Ryan J. Watts, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.45M
-2.04%
Dr. Alexander O. Schuth, M.D.
Dr. Alexander O. Schuth, M.D.
Chief Operating and Financial Officer, Secretary
Chief Operating and Financial Officer, Secretary
806.58K
+0.12%
Mr. Jay T. Flatley
Mr. Jay T. Flatley
Independent Director
Independent Director
358.94K
+1.79%
Dr. David P. Schenkein, M.D.
Dr. David P. Schenkein, M.D.
Independent Director
Independent Director
79.13K
+8.10%
Mr. Peter S. Klein
Mr. Peter S. Klein
Independent Director
Independent Director
33.94K
+18.88%
Ms. Jennifer E. Cook
Ms. Jennifer E. Cook
Independent Director
Independent Director
32.48K
+19.73%
FAQs
Who are the top five shareholders of Denali Therapeutics Inc?
The top five shareholders of Denali Therapeutics Inc are: Dr. Ryan J. Watts, Ph.D.
How many institutions hold shares of Denali Therapeutics Inc (DNLI)?
As of 2026Q1, 555 institutions hold shares of Denali Therapeutics Inc, with a combined market value of approximately 158.73M, accounting for 100.01% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 922456.00.